Atazanavir/Ritonavir (ATV/RTV) Once a Day (QD) + Raltegravir (RAL) Twice a Day (BID) Stable Switch Study (HARNESS)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Bristol-Myers Squibb
ClinicalTrials.gov Identifier:
NCT01332227
First received: April 7, 2011
Last updated: March 10, 2014
Last verified: March 2014
  Purpose

The purpose of this study is to evaluate if HIV-1 infected subjects who are virologically suppressed on a regimen which consists of 2 Nucleoside reverse transcriptase inhibitor's (NRTI) plus any 3rd agent but who are experiencing safety and/or tolerability issues to this regimen will continue to maintain virologic suppression following a switch to a regimen consisting of heat-stable Ritonavir boosted Atazanavir (300/100mg) once daily plus Raltegravir (400mg) twice daily.


Condition Intervention Phase
HIV, Combination Therapy
Drug: Atazanavir
Drug: Ritonavir (heat-stable)
Drug: Raltegravir
Drug: Tenofovir/Emtricitabine
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-Label, Randomized Study Evaluating a Switch From a Regimen of Two Nucleoside Reverse Transcriptase Inhibitors Regimen Plus Any Third Agent to Either a Regimen of Atazanavir/Ritonavir Once Daily and Raltegravir Twice Daily or to a Regimen of Atazanavir/Ritonavir Once Daily and Tenofovir/Emtricitabine Once Daily in Virologically Suppressed HIV-1 Infected Subjects With Safety and/or Tolerability Issues on Their Present Treatment Regimen.

Resource links provided by NLM:


Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures:
  • Proportion of subjects with HIV-1 Ribonucleic acid (RNA) < 40 c/mL through week 24 as measured by quantitative HIV RNA Reverse Transcriptase-Polymerase chain reaction (RT-PCR). [ Time Frame: Week 24 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Proportion of subjects with HIV-1 RNA < 40 c/mL. [ Time Frame: Week 48 ] [ Designated as safety issue: No ]
  • Safety as measured by the frequency of Serious Adverse Events (SAEs), the frequency of Adverse Events(AEs), frequency of AEs leading to discontinuation, the frequency of lab abnormalities and by changes from baseline in fasting lipids. [ Time Frame: Week 24 ] [ Designated as safety issue: Yes ]
  • Safety as measured by the frequency of SAEs, the frequency of AEs, frequency of AEs leading to discontinuation, the frequency of lab abnormalities and by changes from baseline in fasting lipids. [ Time Frame: Week 48 ] [ Designated as safety issue: Yes ]
  • Incidence of resistance and characterization of this resistance following a virological rebound [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
  • Incidence of resistance and characterization of this resistance following a virological rebound [ Time Frame: Week 48 ] [ Designated as safety issue: No ]

Enrollment: 109
Study Start Date: October 2011
Study Completion Date: February 2014
Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1
Atazanavir + Ritonavir (heat-stable) + Raltegravir
Drug: Atazanavir
Capsules, Oral, 300mg, Once daily, 48 weeks
Other Name: Reyataz
Drug: Ritonavir (heat-stable)
Tablets, Oral, 100 mg, Once daily, 48 weeks
Other Name: Norvir
Drug: Raltegravir
Tablets, Oral, 400 mg, Twice daily, 48 weeks
Other Name: Isentress
Arm 2

Reference

Atazanavir + Ritonavir (heat-stable) + Tenofovir/Emtricitabine

Drug: Atazanavir
Capsules, Oral, 300mg, Once daily, 48 weeks
Other Name: Reyataz
Drug: Ritonavir (heat-stable)
Tablets, Oral, 100 mg, Once daily, 48 weeks
Other Name: Norvir
Drug: Tenofovir/Emtricitabine
Tablets, Oral, 300/200 mg, Once daily, 48 weeks
Other Name: Truvada

Detailed Description:

Allocation: Randomized Non-Stratified

Intervention Model: Parallel Versus Comparator(s)

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects who are on a treatment regimen consisting of 2 NRTI + any 3rd agent for at least 3 months immediately prior to screening
  • Subjects who are virologically suppressed (HIV-1 RNA <50 c/mL) for at least 3 months immediately prior to screening
  • Subjects who are virologically suppressed (HIV-1 RNA <40 c/mL) using the Abbott m2000rt® PCR assay) during screening period
  • Subjects who are experiencing treatment related safety and/or tolerability issues to a regimen consisting of 2 NRTI + any 3rd. agent

Exclusion Criteria:

  • History of HAART treatment regimen switch due to virological failure
  • History of genotypic resistance to any component of the study regimen [Atazanavir (ATV), Raltegravir (RAL), Tenofovir/Emtricitabine (TDF/FTC)]
  • History of previous exposure to Atazanavir/Ritonavir (ATV/RTV) or RAL prior to entering the study
  • Subjects experiencing safety and/or tolerability issues to TDF/FTC or RTV
  • Subjects who have switched any component of their Human Immunodeficiency Virus (HIV) Antiretroviral (ARV) medication in the last 3 months immediately prior to screening or during the screening period
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01332227

  Hide Study Locations
Locations
United States, Arkansas
Health For Life Clinic Pllc
Little Rock, Arkansas, United States, 72207
United States, California
Eisenhower Medical Center
Palm Springs, California, United States, 92264
Metropolis Medical Pc
San Francisco, California, United States, 94109
United States, Florida
Consultive Medicine
Daytona Beach, Florida, United States, 32117
Orange County Health Dept.
Orlando, Florida, United States, 32805
Triple O Medical Services, P.A.
West Palm Beach, Florida, United States, 33401
United States, Massachusetts
The Research Institute
Springfield, Massachusetts, United States, 01105
United States, New York
Aids Care
Rochester, New York, United States, 14607
France
Local Institution
Paris, Cedex 12, France, 75551
Local Institution
Lyons Cedex 04, France, 69317
Local Institution
Orleans Cedex 2, France, 45067
Local Institution
Paris, France, 75020
Local Institution
Paris Cedex 14, France, 75679
Local Institution
Strasbourg Cedex, France, 67091
Germany
Local Institution
Bochum, Germany, 44791
Local Institution
Frankfurt, Germany, 60590
Local Institution
Frankfurt Am Main, Germany, 60311
Local Institution
Hamburg, Germany, 20246
Local Institution
Munich, Germany, 80336
Italy
Local Institution
Genova, Italy, 16132
Local Institution
Genova, Italy, 16128
Local Institution
Milano, Italy, 20127
Local Institution
Milano, Italy, 20142
Local Institution
Roma, Italy, 00149
Poland
Local Institution
Warszawa, Poland, 01-201
Local Institution
Wroclaw, Poland, 50-136
Spain
Local Institution
Alicante, Spain, 03010
Local Institution
Barcelona, Spain, 08036
Local Institution
Madrid, Spain, 28046
Local Institution
Madrid, Spain, 28006
Local Institution
Madrid, Spain, 28805
Local Institution
Madrid, Spain, 28007
United Kingdom
Local Institution
London, Greater London, United Kingdom, SW10 9EL
Local Institution
Manchester, Greater Manchester, United Kingdom, M8 5RB
Local Institution
Brighton, United Kingdom, BN2 1ES
Local Institution
London, United Kingdom, NW3 2QG
Local Institution
London, United Kingdom, E9 6SR
Local Institution
Sheffield, United Kingdom, S10 2RX
Sponsors and Collaborators
Bristol-Myers Squibb
Investigators
Study Director: Bristol-Mayers Squibb Bristol-Mayers Squibb
  More Information

Additional Information:
No publications provided

Responsible Party: Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT01332227     History of Changes
Other Study ID Numbers: AI424-402, 2009-017032-41
Study First Received: April 7, 2011
Last Updated: March 10, 2014
Health Authority: United States: Food and Drug Administration
Germany: Federal Institute for Drugs and Medical Devices
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Spain: Ministry of Health
Italy: The Italian Medicines Agency
Poland: Ministry of Health
United Kingdom: Medicines and Healthcare Products Regulatory Agency

Additional relevant MeSH terms:
Reverse Transcriptase Inhibitors
Tenofovir
Tenofovir disoproxil
Ritonavir
Atazanavir
Emtricitabine
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses
HIV Protease Inhibitors
Protease Inhibitors
Anti-HIV Agents

ClinicalTrials.gov processed this record on April 17, 2014